4/A: Unicycive CFO John Townsend Receives RSU Grant

Unicycive Therapeutics CFO John Townsend was granted 169,500 restricted stock units as part of a compensation package.

Summary

• CFO John Townsend received a grant of 169,500 restricted stock units (RSUs) on May 14, 2026.
• The RSU award is payable solely in common stock of Unicycive Therapeutics, Inc.
• 23,542 shares vested immediately upon the grant date.
• The remaining 145,958 shares are scheduled to vest over a 31-month period beginning June 1, 2026, contingent upon continued service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding executive compensation with no material impact on the company's operational outlook.

Positives

• Alignment of executive interests with long-term shareholder value through equity-based compensation.
• Retention mechanism established via a 31-month vesting schedule for the majority of the grant.

Negatives

• Potential for future shareholder dilution upon the conversion of RSUs into common stock.

Risks

• Continued service requirement creates dependency on key personnel retention.
• Market volatility may impact the ultimate value realized by the executive upon vesting.

Future Outlook

The filing does not provide forward-looking financial guidance, focusing solely on executive compensation structure.

Industry Context

StockSavvy.ai notes that equity-based compensation for C-suite executives is standard practice in the biotechnology sector to preserve cash and incentivize long-term performance.

Comparison to Industry Standards

• The use of multi-year vesting schedules for RSUs is consistent with standard corporate governance practices for biotech firms.
• Equity grants for CFOs in small-cap biotech companies typically range between 0.5% to 2% of outstanding shares depending on company stage.

Stakeholder Impact

• Shareholders may experience minor dilution upon the eventual issuance of common stock related to these RSUs.

Next Steps

• Vesting of remaining RSU shares beginning June 1, 2026.

Key Dates

Keywords

Unicycive Therapeutics, UNCY, CFO, Form 4, Insider Trading, Equity Compensation, Restricted Stock Units